Liquid biopsy miRNA signature for melanoma
Xtalks Webinar Presentation
|SPEAKER:||Ryan Van Laar, Ph.D., Founder & CEO, Geneseq Biosciences|
May 21, 2019
Development and Clinical Translation of Melaseq™, a Multi-tissue MicroRNA Profile of Malignant Melanoma, “Australia’s National Cancer”
Australians have the highest incidence of melanoma in the world. Despite extensive public health efforts, new survival-prolonging therapies and record government spending, the mortality rate of this cancer has steadily increased over the past 50 years. Diagnostic imprecision of up to 48 percent and a lack of standardised molecular biomarkers are two factors that are thought to be contributing to Australia’s ongoing melanoma epidemic. As such, there is an urgent need for new, accurate and non-invasive methods to detect, diagnose and monitor this disease.
To identify a signature of cutaneous melanoma that can be detected in both solid tissue and blood, NanoString® miRNA expression profiling was chosen because the NanoString nCounter platform works with small amounts of starting material, is cost-effective and scalable, and has built-in QC and normalization features. Steps in the signature design process, including comparison of microRNA analysis platforms, evaluation of normalization and classification algorithms, and molecular function/pathway analyses, will be discussed in this webinar hosted by Xtalks. Finally, an overview of Geneseq Biosciences’ ongoing technical and clinical validation work, in partnership with one of Australia’s largest private pathology companies, will be presented.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.